Entries for the current year and three preceding years are shown here. Older entries can be found in the archive.
Archive


2010
Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients.
Dickinson L, Jackson AGA, Garvey LJ, Watson V, Khoo SH, Winston A, Boffito M, Davies GR, Back DJ. Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, November 2010, abstract P184.
 
Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.
Dickinson L, Chaponda M, Carr D, van Oosterhout JJ, Kumwenda J, Lalloo DG, Pirmohamed M, Heyderman R, Khoo SH. Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, November 2010, abstract P181.
 
SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients.
Siccardi M, D'Avolio A, Baietto L, Simiele M, Bonora S, Back DJ, Di Perri G, Owen A. Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, November 2010, abstract P178.
 
Therapeutic drug monitoring (TDM) of atazanavir in pregnancy.
Else LJ, Jackson V, Brennan M, Breiden J, WeldridgeC, Coulter-Smith S, Back DJ, Khoo SH, Lambert J. Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, November 2010, abstract P177.
 
Evaluating pharmacist involvement in HIV outpatient clinics: can medication histories, drug interaction checks and adherence assessments add benefit?
Seden K, Back DJ, Khoo SH Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, November 2010, abstract P115.
 
Patients accessing HIV treatment via GUM services - what are the risks of the dual case note system?
Seden K, Mathew T, Friday G, Khoo S.
2nd Joint Conference of the British HIV Association and the British Association for Sexual Health and HIV, Manchester, April 2010, abstract P225.
Population pharmacokinetics of unboosted atazanavir and influence of the pregnane x receptor PXR.
Schipani A, Siccardi M, D'Avolio A, Baietto L, Bonora S, Davies G, Khoo S, Back D, di Perri G, Owen A.
2nd Joint Conference of the British HIV Association and the British Association for Sexual Health and HIV, Manchester, April 2010, abstract P16.
 
Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy.
Lambert J, Else L, Jackson V, Breiden J, Gibbons S, Dickinson L, Back D, Brennan M, Connor EO, Boyle N, Fleming C, Coulter-Smith S, Khoo H.
2nd Joint Conference of the British HIV Association and the British Association for Sexual Health and HIV, Manchester, April 2010, abstract P12.
 
Altered plasma levels of nevirapine after commencing rifampicin containing TB regimens in Malawi.
Chaponda M, Nyirenda W, Watson V, White S, van Oosterhout JJ, Lalloo D, Pirmohamed M, Heyderman R, Mwandumda H, Khoo SH. 11th International Workshop on Clinical Pharmacology of HIV Therapy, Sorrento, April 2010, abstract 46.
 
Investigation of the association of CYP2B6 haplotypes with efavirenz plasma concentrations in a Chilean HIV cohort.
Carr D, La Porte CJL, Egan D, Pirmohamed M, Owen A, Cortes CP. 11th International Workshop on Clinical Pharmacology of HIV Therapy, Sorrento, April 2010, abstract 21.
 
A novel application of population pharmacokinetic analysis: simulating nevirapine dose adjustment according to CYP2B6 516G>T polymorphism.
Schipani A, Mahungu TW, Wyen C, Esser S, Brockmeyer NH, Khoo SH, Johnson M, Davies G, Owen A, and Back DJ. 11th International Workshop on Clinical Pharmacology of HIV Therapy, Sorrento, April 2010, abstract 20.
Intracellular pharmacokinetics of boosted and unboosted atazanavir in HIV infected patients.
Siccardi M, D'Avolio A, Simiele M, Sciandra M, Baietto L, Stefani FR, Agati S, Cusato J, Calcagno A, Owen A, Bonora S, Di Perri G. 11th International Workshop on Clinical Pharmacology of HIV Therapy, Sorrento, April 2010, abstract 17.
 
Evaluating the effect of gender on darunavir and ritonavir exposure in HIV infected subjects (a post-hoc analysis of the GRACE PK sub-study).
Else L, Liptrott N, Moss D, Dutton J, Fraser W, Kakude T, Mrus J, Back D. 11th International Workshop on Clinical Pharmacology of HIV Therapy, Sorrento, April 2010, abstract 11.
 
Application of population pharmacokinetic modelling to quantify the impact of SLCO1B1 521T>C polymorphism on lopinavir clearance.
Schipani A, Egan D, Davies G, Back DJ, Khoo SH, Owen A. 11th International Workshop on Clinical Pharmacology of HIV Therapy, Sorrento, April 2010, abstract 24.
 
Sequential population pharmacokinetic modelling of lopinavir and ritonavir: investigation of different dosing strategies.
Dickinson L, Boffito M, Back D, Else L, von Hentig N, Davies G, Khoo S, Pozniak A, Moyle G, Aarons L. 11th International Workshop on Clinical Pharmacology of HIV Therapy, Sorrento, April 2010, abstract 63.
 
Pharmacogenetics - upcoming applications to patient care.
Owen A. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 113.
 
Genetic variants of ABCC10 are associated with kidney tubular dysfunction in patients treated with tenofovir-containing regimens.
Pushpakom S, Liptrott N, Rodríguez-Nóvoa S, Labarga P, Soriano V, Albalater M, Hopper-Borge E, Back D, Khoo S, and Owen A. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 742.
 
A population pharmacokinetic model illustrates an association between a pregnane-X-receptor (PXR) polymorphism and boosted atazanavir clearance.
Schipani A, Siccardi M, Boffito M, D’Avolio A, Bonora S, Davies G, Khoo S, Back D, Di Perri G, and Owen A. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 618.
 
Raltegravir is a substrate for the influx transporters OAT1 and PEPT1 and the efflux transporter Pgp but is not transported by OATP1A2, OATP1B1, OATP1B3, OCT1, NTCP, or PEPT2.
Moss D, Kwan WS, Liptrott N, Siccardi M, Anstee D, Khoo S, Back D, and Owen A. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 613.
 
Integrating pharmacogenetics and population pharmacokinetic analysis: simulating the impact of CYP2B6 516G>T for 400 mg once daily nevirapine dosing.
Schipani A, Mahungu T, Wyen C, Esser S, Brockmeyer N, Khoo S, Johnson M, Davies G, Owen A, and Back D. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 601.
 
Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS.
Liptrott N, Pushpakom S, Wyen C, Rockstroh J, Mauss S, Knechten H, Brockmeyer N, Hopper-Borge E, Back D, Owen A, and German Competence Network for HIV/AIDS. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 600.
 
Solute carrier organic anion transporter 1B1 (SLCO1B1) mediates transport of maraviroc using a X. leavis model.
Siccardi M, Moss D, Kwan WS, D’Avolio A, Bonora S, Khoo S, Back D, Di Perri G, and Owen A. 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 2010, abstract 599.
top of the page
2009
A population pharmacokinetic model confirms an association between a pregnane-X-receptor (PXR) polymorphism and unboosted atazanavir clearance.
Schipani A, Siccardi M, D'Avolio A, Baietto L, Calcagno A, Tettoni C, Bonora S, Davis G, Khoo S, Back DJ, Di Perri G, Owen A. 12th European AIDS Conference (EACS), Cologne, November 2009, abstract PE 4.1/7.
 
Nevirapine hypersensitivity in Malawi: a prospective cohort study.
Chaponda M, Ooosterhout J, Kumwenda J, Zijlstra E, White S, Lalloo D, Khoo S, Heyderman R, Pirmohamed M. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, April 2009, abstract 0-20.
 
Nevirapine drug exposure in drug-tolerant and hypersensitive Malawian patients.
Chaponda M, Dickinson L, Davies G, Oosterhout J, Kumwenda J, White S, Lalloo D, Heyderman R, Pirmohamed M, Khoo S. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, April 2009, abstract P-60.
 
The prevalence of potential drug-drug interactions in the Swiss HIV Cohort Study.
Gibbons S, Marzolini C, Elzi L, Khoo S, Ledergerber B, Back D, Battegay M, the Swiss HIV Cohort Study Members. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, April 2009, abstract P-33.
 
An exploratory analysis to determine the feasibility of raltegravir population pharmacokinetics in HIV-infected patients and healthy volunteers.
Dickinson L, Back D, Watson V, Davies G, Aarons L, Khoo S, Jackson A, Boffito M. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, April 2009, abstract P-10.
 
Is maraviroc a substrate for SLCO1B1?
Siccardi M, D’Avolio A, Nozza S, Bonora S, Castagna A, Baietto L, Stefani FR, Moss D, Calcagno A, Scinadra M, Lazzarin A, Back D, Owen A, Di Perri G. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, April 2009, abstract P-02.
 
Combined effect of SLCO1B1 521T>C, PXR 63396C>T, and ABCB1 3435C>T on the achievement of therapeutic concentrations of unboosted atazanavir.
Siccardi M, D’Avolio A, Bonora S, Baietto L, Gatti D, Calcagno A, Ghisetti V, Lanzafame M, Penco G, Back D, Owen A, Di Perri G. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, April 2009, abstract O-04.
 
Prevalence of potential drug-drug interactions in the Swiss HIV Cohort Study.
Marzolini C, Gibbons S, Elzi L, Khoo S, Ledergerber B, Battegay M, Back D. 15th Annual Conference of the British HIV Association, Liverpool, April 2009, abstract P141.
 
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected and healthy individuals.
Dickinson L, Aarons L, Back D, Waters L, Else L, Khoo S, Pozniak A, Boffito M. 15th Annual Conference of the British HIV Association, Liverpool, April 2009, abstract P140.
 
Population pharmacokinetics of nevirapine in HIV-infected adults.
Schipani A, Wakeham K, Ggayi A, Kamali A, Lalloo DG, Youle M, Johnson M, Khoo S, Dickinson L, Back D. 15th Annual Conference of the British HIV Association, Liverpool, April 2009, abstract P139.
 
Association between ABCB1 3435C>T and CYP2B6 516G>T and high-density lipoprotein cholesterol (HDL-c) changes in antiretroviral-naïve patients receiving first-line efavirenz-based regimens.
Mahunga TW, Nair D, Smith CJ, Youle M, Johnson MA, Khoo SH, Back DJ, Owen A. 15th Annual Conference of the British HIV Association, Liverpool, April 2009, abstract P133.
 
Nuclear receptor polymorphisms and boosted saquinavir plasma concentrations in HIV-infected subjects.
Chaikan A, Egan D, Gibbons S, Khoo SH, Owen A, Back D. 15th Annual Conference of the British HIV Association, Liverpool, April 2009, abstract O23.
 
Adipogenic gene variants in patients with HIV-associated lipodystrophy.
Pushpakom S, Owen A, Vilar J, Back D, Pirmohamed M. 15th Annual Conference of the British HIV Association, Liverpool, April 2009, abstract O1.
 
The genetic determinants of high-density lipoprotein cholesterol changes in HIV-1-infected adults on efavirenz-based regimens.
Mahunga T, Nair D, Smith C, Turner F, Youle M, Johnson M, Egan D, Khoo S, Back D, Owen A. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, February 2009, abstract 716
Predictors of kidney tubulopathy in HIV patients treated with tenofovir: a pharmacogentic study.
Rodriguez Novoa S, Labarga P, Soriano V, Egan D, Morello J, Gonzalez-Pardo G, Cuenca L, Khoo S, Back D, Owen A. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, February 2009, abstract 37
 
Coadministration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans.
Wakeham K, Ggayi A-B, Watson V, Parkes R, Grosskurth H, Kamali A, Khoo S, Lalloo D. 16th Conference on Retroviruses and Opportunistic Infections, Montreal, February 2009, abstract 700.
top of the page

Last Reviewed: 16 August 2011
Copyright © 1999-2010 The University of Liverpool. All rights reserved. Site developed and maintained by The University of Liverpool and eMedFusion